SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of February 2016
Commission File Number 001-37410
ESSA Pharma Inc.
(Translation of registrant’s name into English)
Suite 720, 999 West Broadway, Vancouver, British Columbia, Canada, V5Z 1K5
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-Fx Form 40-F¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):¨
EXHIBITS INCLUDED AS PART OF THIS REPORT
| Exhibit(s) | |
| | |
| 99.1 | Condensed Consolidated Interim Financial Statements for the Three Months Ended December 31, 2015 and 2014. |
| 99.2 | Management’s Discussion and Analysis for the Three Months Ended December 31, 2015 and 2014 |
| 99.3 | Certification of Interim Filing: CEO |
| 99.4 | Certification of Interim Filing: CFO |
| 99.5 | Press Release: ESSA Pharma Inc. Reports Financial Results for the First Quarter Ended December 31, 2015 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | EssaPharma Inc. |
| | (Registrant) |
| | | |
| Date: February 12, 2016 | By: | /S/ David Wood |
| | Name: | David Wood |
| | Title: | Chief Financial Officer |
